Arcturus Therapeutics ARCT 深 沪
已收盘 10-23 16:00:00 美东时间
9.84
-0.890
-8.29%
华盛通- 最 高10.69
- 今 开10.59
- 成交量 47.50万股
- 最 低 9.75
- 昨 收 10.73
- 总市值 2.80亿
- 52周最高 17.96
- 市盈率 静 --
- 换手率 1.67%
- 52周最低 5.50
- 委 比 59.65%
- 总股本 2842.31万
- 历史最高 129.71
- 量 比 0.75
- 振 幅 8.76%
- 历史最低 4.11
- 每 手 1
- 风险率 2.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅91.5%！巴克莱上调Vertical Aerospace评级至"标配"，目标价下调至1美元
今日重点评级关注：巴克莱：上调Vertical Aerospace评级至"标配"，目标价从2美元降至1美元；巴克莱：维持Bitdeer Technologies"超配"评级，目标价从15美元升至17美元
10-12 14:52
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE:HUM) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved significantly, with 95% of members enrolled in plans earning at least four stars f...
10-09 22:51
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised the price target for Robinhood Markets Inc (NASDAQ:HOOD) from $150 to $160. Morgan Stanl...
10-09 21:11
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
10-09 20:27
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) on Wednesday revealed interim Phase 2 trial data for ARCT-810, its investigational treatment for ornithine transcarbamylase (OTC) deficiency. Following the announcement, the stock gained more than 6%. OTC deficiency is a rare genetic disorder that st...
09-25 02:26
Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. ...
09-18 21:04
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 250 points on Friday. Shares of National Beverage Corp (NASDAQ:FIZZ) fell in pre-market trading following downbeat first-quarter results. National Beverage reported quarterly earnings of 50 cents per share which missed ...
09-11 20:04
美股牛股 | GoPro获YouTube顶流入股暴升40%；Moderna劲升9.9%，mRNA重磅试验再传捷报；爱迪生国际升近9%
GoPro获YouTube顶流入股暴升40%；Moderna劲升9.9%，mRNA重磅试验再传捷报；爱迪生国际升近9%，监管预期改善推动估值修复>>
09-02 18:51
Arcturus, Moderna fall after BioNTech's cancer vaccine setback
Messenger RNA drug developers Arcturus Therapeutics (ARCT) and Moderna (MRNA) traded lower on Friday after BioNTech (BNTX) decided to halt a mid-stage trial for its mRNA-based cancer vaccine BNT122 de...
08-29 02:08
